Spikevax (Moderna mRNA-1273 COVID-19 vaccine) for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo
vs. uncontrolled study

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 2

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

COVE Moderna/NIH phase 3 (study 301), 2020 NCT04470427

Spikevax (Moderna mRNA-1273 COVID-19 vaccine) (n=15181) vs. placebo (n=15170)

randomized controlled trial

Studied treatment

mRNA-1273 vaccine
100 μg of mRNA-1273 two-dose schedule given one month apart

Control treatment

placebo
saline placebo two-dose schedule given one month apart

Patients

COVID-19 prophylaxis (excluding children)

Method

double blind

100 centres, USA

Randomization was stratified based on age and the presence or absence of risk factors for severe illness for COVID-19

Remark

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open